← Back to Program
Evolution
H5

Valuing a Technology Before There’s a Company

Pre-Revenue Valuation in Healthcare Innovation

EVCA valuation principles. Risk-adjusted NPV. Comparable transaction analysis in medtech and biotech. How early-stage valuation sets the structural baseline for everything that follows. The difference between what an angel values and what a strategic acquirer values.

Coming Soon

This evolution is under development. Content will be available when the next cohort begins.

Contact Us
Next cohort begins soon
Next Cohort begins June 17, 2026